Forty-seven clinically relevant late-phase programs identify development trajectories for PD-1 and PD-L1 therapies through 2030
47 late-phase programs aim to improve PD-1/PD-L1 cancer therapies
This narrative review analyzes registry-derived clinical trial data to identify future directions for PD-1 and PD-L1 inhibitor therapies. Th…
A new review maps 47 late-phase programs working to overcome limits of PD-1/PD-L1 cancer treatments through 2030.
Boron neutron capture therapy combined with immunotherapy may enhance anti-tumor response and transform the tumor microenvironment
Novel insights into the clinical translation of BNCT combined with immunotherapy
This narrative review discusses the potential of combining Boron neutron capture therapy (BNCT) with immunotherapy. The authors suggest this…
A narrative review suggests combining Boron neutron capture therapy with immunotherapy may boost anti-tumor responses and change the tumor e…